UA75316C2 - Гомологи з фактором росту фібробласта - Google Patents

Гомологи з фактором росту фібробласта Download PDF

Info

Publication number
UA75316C2
UA75316C2 UA99042170A UA99042170A UA75316C2 UA 75316 C2 UA75316 C2 UA 75316C2 UA 99042170 A UA99042170 A UA 99042170A UA 99042170 A UA99042170 A UA 99042170A UA 75316 C2 UA75316 C2 UA 75316C2
Authority
UA
Ukraine
Prior art keywords
sequence
polypeptide
amino acid
cells
acid residue
Prior art date
Application number
UA99042170A
Other languages
English (en)
Russian (ru)
Ukrainian (uk)
Inventor
Тереза А. ДЕЙШЕР
Деррел К. Конклін
Фенелла К. Реймонд
Томас Р. Буковскі
Сьюзен Д. Голдерман
Бріджіт Гансен
Пол О. ШЕППАРД
Original Assignee
Займодженетікс, Інк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Займодженетікс, Інк. filed Critical Займодженетікс, Інк.
Publication of UA75316C2 publication Critical patent/UA75316C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0657—Cardiomyocytes; Heart cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/119—Other fibroblast growth factors, e.g. FGF-4, FGF-8, FGF-10

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Microbiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Peptides Or Proteins (AREA)
UA99042170A 1996-10-16 1997-10-16 Гомологи з фактором росту фібробласта UA75316C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2864696P 1996-10-16 1996-10-16
PCT/US1997/018635 WO1998016644A1 (en) 1996-10-16 1997-10-16 Fibroblast growth factor homologs

Publications (1)

Publication Number Publication Date
UA75316C2 true UA75316C2 (uk) 2006-04-17

Family

ID=21844629

Family Applications (1)

Application Number Title Priority Date Filing Date
UA99042170A UA75316C2 (uk) 1996-10-16 1997-10-16 Гомологи з фактором росту фібробласта

Country Status (20)

Country Link
US (3) US5989866A (ko)
EP (4) EP2339002A1 (ko)
JP (1) JP4091122B2 (ko)
KR (1) KR100611063B1 (ko)
CN (1) CN1127568C (ko)
AT (2) ATE491029T1 (ko)
AU (1) AU725551B2 (ko)
BR (2) BRPI9712348C8 (ko)
CA (1) CA2269083C (ko)
CZ (1) CZ299288B6 (ko)
DE (2) DE69735352T2 (ko)
DK (2) DK1632574T3 (ko)
ES (3) ES2258788T3 (ko)
HK (2) HK1089206A1 (ko)
IL (1) IL129379A (ko)
NO (1) NO326459B1 (ko)
PL (1) PL192537B1 (ko)
PT (2) PT1632574E (ko)
UA (1) UA75316C2 (ko)
WO (1) WO1998016644A1 (ko)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5728546A (en) 1995-06-05 1998-03-17 Human Genome Sciences, Inc. Fibroblast growth factor 13
US6518236B1 (en) * 1996-10-16 2003-02-11 Zymogenetics, Inc. FGF homologs
US20050043234A1 (en) 1996-10-16 2005-02-24 Deisher Theresa A. Novel FGF homologs
AU5433798A (en) * 1996-11-27 1998-06-22 Human Genome Sciences, Inc. Fibroblast growth factor-13
US6207442B1 (en) * 1997-10-16 2001-03-27 Zymogenetics, Inc. Plasmid construction by homologous recombination
EP1062339A2 (en) * 1998-03-09 2000-12-27 Chiron Corporation Human fgf gene and gene expression products
ATE226444T1 (de) * 1998-03-12 2002-11-15 Genentech Inc Verwendung von fgf-5 polypetiden zur vorbeugung des absterbens retinaler neuronen und behandlung okularer krankheiten
US6331523B1 (en) 1998-03-12 2001-12-18 Genentech, Inc. Method of enhancing the survival of retinal neurons and treating ocular diseases using FGF-5
AU5081899A (en) * 1998-07-20 2000-02-14 Curagen Corporation Nucleotide sequences and amino acid sequences of secreted proteins involved in angiogenesis
US6537554B1 (en) 1998-09-10 2003-03-25 Curagen Corporation Nucleotide sequences and amino acid sequences of secreted proteins involved in angiogenesis
US6251079B1 (en) 1998-09-30 2001-06-26 C. R. Bard, Inc. Transthoracic drug delivery device
US6635249B1 (en) 1999-04-23 2003-10-21 Cenes Pharmaceuticals, Inc. Methods for treating congestive heart failure
CA2385498C (en) * 1999-09-30 2013-01-08 Kaken Pharmaceutical Co., Ltd. Method to enhance healing of sternum after sternotomy
US7470665B2 (en) 1999-12-02 2008-12-30 Zymogenetics, Inc. Methods for targeting cells that express fibroblast growth receptor-3 or -2
EP1234033B1 (en) * 1999-12-02 2011-12-28 ZymoGenetics, Inc. Methods for targeting cells that express fibroblast growth factor receptor-3 or-2
US7288521B2 (en) * 2000-04-06 2007-10-30 Franco Wayne P Growth factor therapy mobilization of stem cells into the peripheral blood
US7291597B2 (en) * 2000-04-06 2007-11-06 Franco Wayne P Growth factor therapy mobilization of stem cells into the peripheral blood
IL139380A0 (en) * 2000-10-31 2001-11-25 Prochon Biotech Ltd Active variants of fibroblast growth factor
AU2002355844A1 (en) * 2001-08-01 2003-02-17 New York University Identification of receptor and heparin binding sites in fgf4 by structure-based mutagenesis
CA2471938A1 (en) * 2001-12-28 2003-07-17 Kyowa Hakko Kogyo Co., Ltd. Agent for treating arthritis
IL149562A0 (en) 2002-05-09 2002-11-10 Prochon Ltd Fgf variants and methods for use thereof
WO2004002469A1 (de) * 2002-06-29 2004-01-08 Aquanova German Solubilisate Technologies (Agt) Gmbh Isoflavonkonzentrate sowie verfahren zu ihrer herstellung
US7166574B2 (en) 2002-08-20 2007-01-23 Biosurface Engineering Technologies, Inc. Synthetic heparin-binding growth factor analogs
US8227411B2 (en) 2002-08-20 2012-07-24 BioSurface Engineering Technologies, Incle FGF growth factor analogs
US7981862B2 (en) 2003-08-19 2011-07-19 Biosurface Engineering Technologies, Inc. Composition comprising BMP-2 amplifier/co-activator for enhancement of osteogenesis
US7598224B2 (en) 2002-08-20 2009-10-06 Biosurface Engineering Technologies, Inc. Dual chain synthetic heparin-binding growth factor analogs
US20040136970A1 (en) * 2002-10-07 2004-07-15 Ellsworth Jeff L. Methods for administering FGF18
AU2004226421A1 (en) * 2003-03-27 2004-10-14 Children's Hospital Medical Center Use of FGF- 18 protein, target proteins and their respective encoding nucleotide sequences to induce cartilage formation
US7067123B2 (en) 2003-04-29 2006-06-27 Musculoskeletal Transplant Foundation Glue for cartilage repair
US7901457B2 (en) 2003-05-16 2011-03-08 Musculoskeletal Transplant Foundation Cartilage allograft plug
US7414028B1 (en) 2004-02-04 2008-08-19 Biosurface Engineering Technologies, Inc. Growth factor analogs
US20060024347A1 (en) * 2004-02-10 2006-02-02 Biosurface Engineering Technologies, Inc. Bioactive peptide coatings
US7671012B2 (en) 2004-02-10 2010-03-02 Biosurface Engineering Technologies, Inc. Formulations and methods for delivery of growth factor analogs
US7528105B1 (en) 2004-02-10 2009-05-05 Biosurface Engineering Technologies Heterodimeric chain synthetic heparin-binding growth factor analogs
US20080227696A1 (en) 2005-02-22 2008-09-18 Biosurface Engineering Technologies, Inc. Single branch heparin-binding growth factor analogs
WO2005082005A2 (en) 2004-02-20 2005-09-09 Biosurface Engineering Technologies, Inc., Et Al. Positive modulator of bone morphogenic protein-2
EP1896053B1 (en) 2004-07-06 2018-10-31 ZymoGenetics, Inc. Pharmaceutical composition comprising fgf18 and il-1 antagonist and method of use
US20090319045A1 (en) 2004-10-12 2009-12-24 Truncale Katherine G Cancellous constructs, cartilage particles and combinations of cancellous constructs and cartilage particles
US7837740B2 (en) 2007-01-24 2010-11-23 Musculoskeletal Transplant Foundation Two piece cancellous construct for cartilage repair
US7858341B2 (en) * 2004-12-10 2010-12-28 Zymogenetics, Inc. FGF18 production in prokaryotic hosts
US7815926B2 (en) 2005-07-11 2010-10-19 Musculoskeletal Transplant Foundation Implant for articular cartilage repair
WO2007035778A2 (en) 2005-09-19 2007-03-29 Histogenics Corporation Cell-support matrix and a method for preparation thereof
JPWO2007099953A1 (ja) * 2006-02-28 2009-07-16 国立大学法人 東京医科歯科大学 歯根形成促進剤及び歯根形成促進方法
US8298528B2 (en) * 2006-04-17 2012-10-30 Hepacore Ltd. Methods for bone regeneration using endothelial progenitor cell preparations
US7820172B1 (en) 2006-06-01 2010-10-26 Biosurface Engineering Technologies, Inc. Laminin-derived multi-domain peptides
US8962556B2 (en) * 2006-09-28 2015-02-24 Prochon Biotech Ltd. FGF-2 variants having N-terminal deletions and increased receptor selectivity and uses thereof
US7696171B1 (en) * 2006-11-09 2010-04-13 The Florida State University Research Foundation, Inc. Mutant polypeptides of fibroblast growth factor 1
EP2127674B1 (en) * 2007-02-19 2013-04-24 National Institute of Advanced Industrial Science and Technology Use of FGF18 inhibitors as hair regrowth promoter
US8435551B2 (en) 2007-03-06 2013-05-07 Musculoskeletal Transplant Foundation Cancellous construct with support ring for repair of osteochondral defects
US7659379B1 (en) * 2007-05-24 2010-02-09 Florida State University Research Foundation, Inc. Mutants of human fibroblast growth factor having increased stability and/or mitogenic potency
US8685107B2 (en) 2007-07-03 2014-04-01 Histogenics Corporation Double-structured tissue implant and a method for preparation and use thereof
US20090054984A1 (en) 2007-08-20 2009-02-26 Histogenics Corporation Method For Use Of A Double-Structured Tissue Implant For Treatment Of Tissue Defects
TWI527590B (zh) 2011-06-17 2016-04-01 艾瑞斯貿易公司 Ｆｇｆ－１８之凍乾調配物
EP2880179B1 (en) 2012-08-06 2017-12-13 Merck Patent GmbH Genetic markers for predicting responsiveness to fgf-18 compound
US10077420B2 (en) 2014-12-02 2018-09-18 Histogenics Corporation Cell and tissue culture container
KR102261934B1 (ko) * 2015-01-23 2021-06-08 (주) 에스바이오메딕스 Mbp-fgf2를 이용한 3차원 섬유아세포집합체를 제조하는 방법
US20180024142A1 (en) 2015-01-29 2018-01-25 Ares Trading S.A. Immunoassays for high positively charged proteins
CN107849151B (zh) * 2015-07-15 2022-05-24 德益阳光生物技术（北京）有限责任公司 融合多肽及使用方法
BR112020005035A2 (pt) 2017-09-21 2020-09-15 Merck Patent Gmbh proteína de fusão comprendendo porção fgf-18
CN111163791A (zh) 2017-09-29 2020-05-15 默克专利有限公司 预测对fgf-18化合物反应性的代谢生物标志物
US11467169B2 (en) 2017-09-29 2022-10-11 Merck Patent Gmbh Inflammatory biomarkers for predicting responsiveness to FGF-18 compound
CN108324928B (zh) * 2018-03-05 2020-09-08 哈尔滨医科大学 重组人成纤维细胞生长因子-5在促骨折愈合中的应用

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE54046B1 (en) 1981-08-25 1989-05-24 Celltech Ltd Expression vectors
US4579821A (en) 1981-11-23 1986-04-01 University Patents, Inc. Control of DNA sequence transcription
US4656134A (en) 1982-01-11 1987-04-07 Board Of Trustees Of Leland Stanford Jr. University Gene amplification in eukaryotic cells
US4486533A (en) 1982-09-02 1984-12-04 St. Louis University Filamentous fungi functional replicating extrachromosomal element
US4599311A (en) 1982-08-13 1986-07-08 Kawasaki Glenn H Glycolytic promotersfor regulated protein expression: protease inhibitor
US4977092A (en) 1985-06-26 1990-12-11 Amgen Expression of exogenous polypeptides and polypeptide products including hepatitis B surface antigen in yeast cells
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
US5139936A (en) 1983-02-28 1992-08-18 Collaborative Research, Inc. Use of the GAL1 yeast promoter
US4661454A (en) 1983-02-28 1987-04-28 Collaborative Research, Inc. GAL1 yeast promoter linked to non galactokinase gene
US4870008A (en) 1983-08-12 1989-09-26 Chiron Corporation Secretory expression in eukaryotes
US4945778A (en) 1984-01-30 1990-08-07 Weyer Paul P Fluid-power device with rollers
US4931373A (en) 1984-05-25 1990-06-05 Zymogenetics, Inc. Stable DNA constructs for expression of α-1 antitrypsin
US4766073A (en) 1985-02-25 1988-08-23 Zymogenetics Inc. Expression of biologically active PDGF analogs in eucaryotic cells
DE3578435D1 (de) 1984-12-06 1990-08-02 Labofina Sa Promotoren fuer die expression von fremden genen in hefe, plasmide, die diese promotoren enthalten, sowie deren verwendung zur herstellung von polypeptiden.
US4775624A (en) 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
GR860984B (en) 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
US5604293A (en) * 1985-09-12 1997-02-18 Scios Inc. Recombinant human basic fibroblast growth factor
US5439818A (en) * 1985-09-12 1995-08-08 Scios Nova Inc. DNA encoding human recombinant basic fibroblast growth factor
US4882279A (en) 1985-10-25 1989-11-21 Phillips Petroleum Company Site selective genomic modification of yeast of the genus pichia
US4935349A (en) 1986-01-17 1990-06-19 Zymogenetics, Inc. Expression of higher eucaryotic genes in aspergillus
GB8611832D0 (en) 1986-05-15 1986-06-25 Holland I B Polypeptide
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5063154A (en) 1987-06-24 1991-11-05 Whitehead Institute For Biomedical Research Pheromone - inducible yeast promoter
US4956288A (en) 1988-04-22 1990-09-11 Biogen, Inc. Method for producing cells containing stably integrated foreign DNA at a high copy number, the cells produced by this method, and the use of these cells to produce the polypeptides coded for by the foreign DNA
US5037743A (en) 1988-08-05 1991-08-06 Zymogenetics, Inc. BAR1 secretion signal
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5162228A (en) 1988-12-28 1992-11-10 Takeda Chemical Industries, Ltd. Gylceraldehyde-3-phosphate dehydrogenase gene and promoter
US5162222A (en) 1989-07-07 1992-11-10 Guarino Linda A Use of baculovirus early promoters for expression of foreign genes in stably transformed insect cells or recombinant baculoviruses
IL99552A0 (en) 1990-09-28 1992-08-18 Ixsys Inc Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
CA2144651A1 (en) 1992-09-14 1994-03-31 Timothy J. Miller Immortalized cells and uses therefor
US5773252A (en) 1995-06-05 1998-06-30 Human Genome Sciences, Inc. Fibroblast growth factor 15
EP0889966A1 (en) 1995-11-09 1999-01-13 ZymoGenetics, Inc. Compositions and methods for producing heterologous polypeptides in pichia methanolica

Also Published As

Publication number Publication date
HK1148030A1 (en) 2011-08-26
ES2403880T3 (es) 2013-05-22
AU4758397A (en) 1998-05-11
EP1632574A1 (en) 2006-03-08
WO1998016644A1 (en) 1998-04-23
KR20000049207A (ko) 2000-07-25
BR9712348A (pt) 1999-08-31
EP2264175B1 (en) 2012-11-21
CN1247568A (zh) 2000-03-15
US6352971B1 (en) 2002-03-05
US20040096936A1 (en) 2004-05-20
EP0931148B1 (en) 2006-03-01
DK1632574T3 (da) 2011-02-28
PL332851A1 (en) 1999-10-25
ES2258788T3 (es) 2006-09-01
DK0931148T3 (da) 2006-06-19
EP2264175A1 (en) 2010-12-22
PT931148E (pt) 2006-06-30
NO991796D0 (no) 1999-04-15
EP0931148A1 (en) 1999-07-28
BRPI9712348C8 (pt) 2020-04-22
CA2269083C (en) 2009-06-09
CZ299288B6 (cs) 2008-06-04
CA2269083A1 (en) 1998-04-23
DE69735352D1 (de) 2006-04-27
US7247608B2 (en) 2007-07-24
JP2001502178A (ja) 2001-02-20
DE69735352T2 (de) 2006-10-12
BR9712348B1 (pt) 2013-06-18
PL192537B1 (pl) 2006-11-30
US5989866A (en) 1999-11-23
JP4091122B2 (ja) 2008-05-28
EP2339002A1 (en) 2011-06-29
IL129379A0 (en) 2000-02-17
ATE318906T1 (de) 2006-03-15
AU725551B2 (en) 2000-10-12
CZ131599A3 (cs) 1999-11-17
DE69740074D1 (de) 2011-01-20
PT1632574E (pt) 2011-03-17
ATE491029T1 (de) 2010-12-15
IL129379A (en) 2008-12-29
KR100611063B1 (ko) 2006-08-09
NO991796L (no) 1999-06-16
HK1089206A1 (en) 2006-11-24
NO326459B1 (no) 2008-12-08
EP1632574B1 (en) 2010-12-08
CN1127568C (zh) 2003-11-12
ES2357215T3 (es) 2011-04-20

Similar Documents

Publication Publication Date Title
UA75316C2 (uk) Гомологи з фактором росту фібробласта
Johnson et al. Autocrine action of amphiregulin in a colon carcinoma cell line and immunocytochemical localization of amphiregulin in human colon.
US5840525A (en) Nucleic acids, vectors and host cells encoding heregulin
Burgess et al. Biosynthetic processing of neu differentiation factor: glycosylation, trafficking, and regulated cleavage from the cell surface
Speir et al. Acidic and basic fibroblast growth factors in adult rat heart myocytes. Localization, regulation in culture, and effects on DNA synthesis.
WO1996015244A2 (en) Sensory and motor neuron derived factor (smdf)
CN101896501A (zh) 靶向破骨细胞相关蛋白Siglec-15的抗体
CS91791A3 (en) Epithelium or epithelium precursors
US6225088B1 (en) DNA encoding plasminogen-like growth factor (PLGF) and related embodiments
AU736328B2 (en) Morphogenic proteins
AU5081899A (en) Nucleotide sequences and amino acid sequences of secreted proteins involved in angiogenesis
EP1627051A2 (en) Regulation of acheron expression
US5147798A (en) Monophenotypic xenograft of megakaryocytic lineage and origin
CA2191321A1 (en) Gene coding for modified bone morphogenic protein receptor
WO1998037195A9 (en) Morphogenic proteins
JP2002514386A (ja) ヒトｆｇｆ遺伝子および遺伝子発現産物
CA2245635A1 (en) Cardiotrophin and uses therefor
JPH05506659A (ja) エピテリン類：新規なシステインに富む成長変調タンパク
JPH08169898A (ja) ペプチド及びモノクローナル抗体